Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $4.93 Million - $6 Million
-86,100 Reduced 85.67%
14,400 $866,000
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $6.35 Million - $7.69 Million
100,500 New
100,500 $6.75 Million
Q2 2022

Aug 15, 2022

SELL
$33.54 - $55.0 $1.19 Million - $1.96 Million
-35,600 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $936,804 - $1.46 Million
30,200 Added 559.26%
35,600 $1.29 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $222,156 - $307,692
5,400 New
5,400 $252,000
Q3 2021

Nov 15, 2021

SELL
$35.31 - $50.56 $296,604 - $424,704
-8,400 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$25.8 - $41.09 $216,720 - $345,156
8,400 New
8,400 $345,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.7B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.